8 completed, 2 recruiting, 1 terminated. 3 Phase 2, 3 Phase 3, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Non-metastatic Prostate Cancer: new trials by email Literature Review of Non-metastatic Prostate Cancer trials Research Report on Non-metastatic Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation Therapy Approaches for People With Prostate Cancer Standard of Care HDR Brachytherapy, SBRT - Prostate Cancer Patients, Non-metastatic Prostate Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 126 | 2026-07-31 | 2026-08-12 |
| Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer. Experimental: DaRT seeds - Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer | Not applicable | Recruiting | Alpha Tau Medical LTD. | 10 | 2024-03-12 | 2026-06-16 |
| An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide - Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer | Completed | Bayer | 1800 | 2024-01-05 | 2024-04-09 | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate - Metastatic Prostate Cancer, Non-metastatic Prostate Cancer | Phase 1 | Terminated | Praful Ravi, MB BCHir, MRCP | 9 | 2023-08-09 | 2026-10-15 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Darolutamide, Enzalutamide - Metastatic Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 111 | 2021-08-17 | 2026-09-21 |
| PROState Pathway Embedded Comparative Trial Prostate Cancer, Non-metastatic Prostate Cancer | Completed | Imperial College London | 139 | 2020-09-08 | 2025-06-18 | |
| Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], Focal therapy, Focal therapy after Finasteride 5Mg tablets for 12 weeks - Prostate Cancer, Non-metastatic Prostate Cancer | Not applicable | Completed | Imperial College London | 100 | 2019-12-11 | 2025-03-24 |
| Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer Gefitinib, radiotherapy - Non-Metastatic Prostate Cancer | Phase 1 / Phase 2 | Completed | AstraZeneca | 42 | 2003-01-01 | 2009-04-23 |
| Casodex vs Placebo in Non-Metastatic Early Prostate Cancer Bicalutamide, Placebo - Non-Metastatic Prostate Cancer | Phase 3 | Completed | AstraZeneca | 1218 | 1995-10-01 | 2009-05-27 |
| (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer Bicalutamide, Placebo - Non-Metastatic Prostate Cancer | Phase 3 | Completed | AstraZeneca | 3588 | 1995-09-01 | 2010-12-10 |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Bicalutamide, Placebo - Non-metastatic Prostate Cancer | Phase 3 | Completed | AstraZeneca | 3618 | 1995-08-01 | 2012-06-06 |
Genital Diseases (9) · Genital Diseases, Male (9) · Genital Neoplasms, Male (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9)
bicalutamide (3) · darolutamide (3) · Radiotherapy (2) · enzalutamide (2) · Brachytherapy (1) · Cryotherapy (1) · Gefitinib (1) · Goserelin (1) · Leuprolide (1) · Neoadjuvant Therapy (1) · Prostatectomy (1) · WW Domain-Containing Oxidoreductase (1) · abemaciclib (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · apalutamide (1)
AstraZeneca (4) · Imperial College London (2) · Alliance Foundation Trials, LLC. (1) · Alpha Tau Medical LTD. (1) · Bayer (1) · Memorial Sloan Kettering Cancer Center (1) · Praful Ravi, MB BCHir, MRCP (1)
United States (5) · United Kingdom (3) · Finland (2) · Israel (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Ireland (1) · Italy (1) · Mexico (1)
Hashim Ahmed (2) · Daniel Gorovets, MD (1) · David G. McLeod (1) · Evanthia Galanis, MD (1) · Manfred P Wirth, Professor (1) · Peter Iversen, MD (1) · Praful Ravi, MB BChir, MRCP (1) · Tomer Charas, MD (1) · William See (1)
PMID 22129214, PMID 26681677, PMID 32302790, PMID 35963650
P50CA272390 (1)